Latest Commercial Scale Up News

Firebird Metals has locked in a purpose-built industrial facility in Osborne Park, Perth, to house its pioneering Australian Demonstration Plant, the only fully integrated manganese concentrate-to-cathode active material facility outside China.

Prairie Lithium has moved Pad #1 from groundwork to active building construction, backed by SaskPower's powerline installation and a binding Hydro Lithium offtake agreement that includes a A$10 million equipment contribution. First production is targeted for Q4 2026.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Clean TeQ Water boosted its cash position and operational momentum in Q3 FY26, winning a A$10.4 million DESALX execution contract at Nyrstar Belgium, completing a uranium plant at Heathgate Resources, and advancing lithium and phosphate projects internationally.

Volt Resources has secured a major extension and volume increase to its Bunyu graphite offtake agreement while progressing high purity graphite production and downstream refinery development in the US.

HyTerra Ltd is progressing its flagship Nemaha hydrogen project with a key production test planned for Q2 2026, while expanding its global footprint through strategic partnerships and a $7 million capital raise.

Metal Powder Works has scaled its NextGen powder production to 100 metric tonnes per annum with an industry-leading saleable yield above 95%, setting the stage for an 800MT capacity by 2028 at a fraction of conventional costs.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Cleo Diagnostics has kicked off a staged manufacturing program with Bio-Techne to produce ovarian cancer test kits, moving from clinical sample collection to analytical validation and FDA submission preparation.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.